Role of genetic testing in patients undergoing percutaneous coronary intervention.

ABSTRACT:

Introduction

Variability in individual response profiles to antiplatelet therapy, in particular clopidogrel, is a well-established phenomenon. Genetic variations of the cytochrome P450 (CYP) 2C19 enzyme, a key determinant in clopidogrel metabolism, have been associated with clopidogrel response profiles. Moreover, the presence of a CYP2C19 loss-of-function allele is associated with an increased risk of atherothrombotic events among clopidogrel-treated patients undergoing percutaneous coronary interventions (PCI), prompting studies evaluating the use of genetic tests to identify patients who may be potential candidates for alternative platelet P2Y₁₂ receptor inhibiting therapies (prasugrel or ticagrelor). Areas covered: The present manuscript provides an overview of genet

SUBMITTER: Moon JY 

PROVIDER: S-EPMC5771818 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature